Norman Taylor

RESEARCH:

Chronic pain has a profound cumulative impact on our nation, affecting over 100 million Americans a day, at a cost of $500 billion in health care and lost productivity each year. Pain is a complex, subjective experience that displays considerable variability compared to other sensory modalities. For instance, in some people intense noxious stimuli are not reported as painful, whereas others can experience excruciating pain from light touching of the skin. Some people are highly sensitive to pain relief from placebo administration, while others are insensitive to even high doses of morphine. Following nerve injury, only a small proportion of people go on to develop neuropathic pain. Our research is focused on uncovering and explaining the sources of variability in these phenomena.

Ongoing projects in the lab include:

1. It is well known that the descending spinal pathway, which projects from the periaqueductal gray (PAG) to the rostral ventral medulla (RVM) and terminates at the dorsal horn of the spinal cord, is a powerful modulator of ascending nociceptive signals, and is a primary target of the analgesic actions of opioids and cannabinoids. Less well known is that within the ventral lateral PAG resides a population of dopamine neurons.  Little is known about the function of these neurons in pain and analgesia. We are currently elucidating the circuit interactions of these neurons using electrophysiologic, optogenetic, chemogenetic, pharmacologic and behavioral techniques in transgenic mice. 

2. Just like in humans, there is tremendous diversity in the sensitivity to painful stimuli experienced by different strains of rats. However, no one has previously tried to characterize these differences or determine the genetic causes in a systematic way. In this project, we are using transcriptome profiling(RNA-seq) along with congenic, consomic, transgenic and epigenetic strategies to identify novel pathways responsible for the susceptibility to, or protection from, the progression from acute to chronic pain.  Current pathways of interest include COMT and cathecholamine levels, and inflammation. 

3. Developing a novel model of temporomandibular disorder (TMD) in rats to characterize the effect of genetics, gender and sleep deprivation on the susceptibility to developing temporomandibular pain. No one has previously combined into one model a clinically relevant insult in genetically predisposed female rats using an operant behavioral endpoint to study the physiologic causes and consequences of TMD. Developing such a model would be a huge advance in the field. We expect the findings of this study will help clarify the human gender dimorphism in orofacial pain produced by TMDs, and will provide insight about gender-specific therapeutic strategies for this condition. 

 My Bibliography: